PRT12396 Clinical Trials (2026): 1 Studies for Myelofibrosis (MF) & Myeloproliferative Neoplasms (MPNs)
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 PRT12396 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Myelofibrosis (MF) & Myeloproliferative Neoplasms (MPNs)) and 100 total planned enrollment. 1 PRT12396 clinical trial is actively recruiting at 5 U.S. sites across 5 states. Most recent activity: NCT07469891 (Apr 2028).
Where to Participate: All PRT12396 Trial Sites in the U.S. (5 sites across 5 states)
Every actively recruiting PRT12396trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CO | Colorado Blood Cancer Institute | Denver80218 | NCT07469891 | Map |
| FL | BRCR Global - Coral Springs | Coral Springs33065 | NCT07469891 | Map |
| MI | START Midwest, LLC | Grand Rapids49546 | NCT07469891 | Map |
| PA | Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Trials Office | Philadelphia19107 | NCT07469891 | Map |
| TN | Tristar BMT | Nashville37203 | NCT07469891 | Map |
PRT12396 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
Recruiting PRT12396 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07469891 | A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms | P1 | Polycythemia Vera (PV) | 100 | Apr 2026 |
All PRT12396 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07469891 | A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms | P1 | recruiting | 100 | Prelude Therapeutics | Apr 2026 |
PRT12396 clinical trials: frequently asked questions
- How many PRT12396 clinical trials are there?
- 1 PRT12396 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are PRT12396 clinical trials recruiting in 2026?
- Yes — 1 PRT12396 trial is actively recruiting in 2026, with 5 U.S. sites across 5 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is PRT12396 being studied for?
- PRT12396 is being studied for Myelofibrosis (MF), Myeloproliferative Neoplasms (MPNs), Polycythemia Vera (PV), Post-Essential Thrombocythemia Myelofibrosis, Post-Polycythemia Vera Myelofibrosis and 1 more. The trials are grouped by indication on this page.
- What phase is PRT12396 in?
- PRT12396 clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors PRT12396 clinical trials?
- The lead sponsor across the most PRT12396 trials is Prelude Therapeutics. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming PRT12396as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: